TG Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on TG Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date TG Therapeutics Inc Strategy Report
- Understand TG Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
TG Therapeutics Inc (TG Therapeutics) is a biopharmaceutical company which acquires, develops and commercializes pharmaceutical products for the treatment of B-cell malignancies and various autoimmune diseases. The company’s approved products in the US include Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma. The pipeline products of the company include TG-1701 and TG-1801 for the treatment of B-cell cancers and other diseases. The company also evaluates products and technologies for in-licensing, partnership, acquisition, and investment. The company has operations in the US and Australia. TG Therapeutics is headquartered in New York City, New York, the US.
Headquarters
United States of America
Address
3020 Carrington Mill Blvd., Suite 475, Morrisville, North Carolina, 27560-5435
Website
www.tgtherapeutics.com
Telephone
1 212 5544484
No of Employees
244
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TGTX (NASD)
Revenue (2022)
$2.8M
-58.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
43%
(2022 vs 2021)
Market Cap*
$2.4B
Net Profit Margin (2022)
XYZ
-36.9%
(2022 vs 2021)
* As of and is in US$
TG Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | - |
| Ukoniq: | Ukoniq |
| Marginal Zone Lymphoma | TG Patient Support |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, the company and Neuraxpharm Group entered into an agreement for the commercialization of BRIUMVI (ublituximab) in Europe. |
| 2023 | Regulatory Approval | In June, the company received the European Commission's approval of BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis |
| 2023 | New Products/Services | In January, the company launched BRIUMVI (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis. |
Competitor Comparison
| Key Parameters | TG Therapeutics Inc | Acorda Therapeutics Inc | Infinity Pharmaceuticals Inc | Cyclacel Pharmaceuticals Inc | Hoffmann-La Roche Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Morrisville | Pearl River | Cambridge | Berkeley Heights | Essex County |
| State/Province | North Carolina | New York | Massachusetts | New Jersey | New Jersey |
| No. of Employees | 244 | 111 | 30 | 12 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael S. Weiss | Chairman; Chief Executive Officer; President | Executive Board | 2011 | - |
| Sean A. Power | Chief Financial Officer | Senior Management | 2011 | - |
| Adam Waldman | Chief Commercial Officer | Senior Management | 2018 | - |
| Laurence N. Charney | Director | Non Executive Board | 2012 | 76 |
| Yann Echelard, Ph.D. | Director | Non Executive Board | 2012 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward